Study Summary
This trial is testing a new drug to see if it's safe and effective for people with cancer who can't be treated with other available options.
- Solid Tumors, Adult
Treatment Effectiveness
Study Objectives
2 Primary · 11 Secondary · Reporting Duration: Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year
Trial Safety
Trial Design
3 Treatment Groups
Phase 1 Regimen 1
1 of 3
Phase 1 Regimen 2
1 of 3
Phase 2
1 of 3
Experimental Treatment
300 Total Participants · 3 Treatment Groups
Primary Treatment: ASTX029 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Munck, Joanne M., Valerio Berdini, Luke Bevan, Jessica L. Brothwood, Juan Castro, Aurélie Courtin, Charlotte East, et al.. 2021. “ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK”. Molecular Cancer Therapeutics. American Association for Cancer Research (AACR). doi:10.1158/1535-7163.mct-20-0909.
- Munck, Joanne M., Valerio Berdini, Luke Bevan, Jessica L. Brothwood, Juan Castro, Aurélie Courtin, Charlotte East, et al.. 2021. “ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK”. Molecular Cancer Therapeutics. American Association for Cancer Research (AACR). doi:10.1158/1535-7163.mct-20-0909.
- 2018. "Study of ASTX029 in Subjects With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03520075.
Frequently Asked Questions
How many centers are managing this research?
"This research is currently running at 19 sites, with locations ranging from Boston to Iowa City. To reduce the need for travel, it may be prudent to select a trial site close by." - Anonymous Online Contributor
What is the primary aim of this research endeavor?
"Astex Pharmaceuticals, Inc., the study sponsor, outlines Safety (Phase 1) - Dose-limiting toxicities and Treatment Emergent Adverse Events as their primary outcome. This efficacy of this measure will be assessed over a 6 month to one year period, from Baseline to progressive disease or start of new anticancer therapy. Secondary outcomes include Efficacy - Duration of Response (DOR), Pharmacokinetic profile expressed in terms of Area Under the Time-Concentration Curve (AUC), and Progressive Free Survival (PFS)." - Anonymous Online Contributor
Is enrollment still open for this experiment?
"Data from clinicaltrials.gov confirms that this medical experiment is in need of applicants. The trial was published initially on May 10th 2018 and underwent its most recent update on November 18th 2022." - Anonymous Online Contributor
What is the magnitude of enrollment for this clinical assessment?
"This clinical trial necessitates 300 participants that meet the predetermined criteria for inclusion. Individuals have the chance to take part in this research from both Dana Farber Cancer Institute in Boston, Massachusetts and City of Hope Comprehensive Cancer Center located in Duarte, California." - Anonymous Online Contributor